About Comms

This author has not yet filled in any details.
So far Comms has created 401 blog entries.

INFANT team members WIN at Ideate Ireland Competition

By |2022-07-05T12:34:05+01:00July 5th, 2022|

INFANT Lead Investigator Dr Mark O’SullivanĀ andĀ Dr Alison O’Shea of the Neurobell project are the overall winners of the 2022 Ideate Ireland competition which took place last week.

TheĀ  €15,000 top prize was awarded to Neurobell a pocket-sized brain monitor with automated seizure detection for newborns, which builds on the previous research of the INFANT Research Centre in the field of AI-based interpretation of neonatal EEG.

“The Ideate programme really pushed us to challenge our market assumptions by completing customer discovery across different stakeholder groups,” said O’Sullivan.

“We now have a clear understanding of where the clinical need for our technology is greatest and how best to target that market. It is a key milestone in getting us ready for private investment, and winning the competition will provide us with the momentum and support to bring our product to market successfully.ā€

INFANT researcher Sarusha PillayĀ and INFANT PI Dr Fergus McCarthy won the first runner up prize of €7,000 for their project pHetalSafe, which seeks to detect and prevent fetal hypoxia and assess fetal well-being during labour.

We are immensely proud of our colleagues for this amazing achievement. We look forward to the expansion of their work and wish them the very best in achieving their global ambition.

INFANT Seminar Series

By |2022-06-27T10:13:12+01:00June 27th, 2022|

šŸ“£Final #SeminarSeries before summer break takes place this Friday at 12pm!
Ā 
šŸ—£ Sonia Lenehan will speak about Science4SightLoss
Ā 
šŸ’”Science4SightLoss is an SFI Discover funded collaboration between INFANT, UCC and Ireland’s national sight loss agency the National Council for the Blind (NCBI). Sonia will present a project update with preliminary results.
Ā 
#Science4Sightloss #UCCResearch

New paper by PI’s Dr Ali Khashan and Dr Fergus McCarthy

By |2022-06-23T10:02:26+01:00June 23rd, 2022|

šŸ‘Check out this new paper just out from INFANT Principal Investigators Dr Ali Khashan and Dr Fergus McCarthy

šŸ’”’Role of Antihypertensive Treatment and Blood Pressure Control in the Occurrence of Adverse Pregnancy Outcomes: a Population-Based Study of Linked Electronic Health Records’

Read publication here

#UCCResearchĀ #PregnancyResearch

New Study Protocol by ICAT Fellow Dr Cathal O’Connor

By |2022-06-23T09:45:54+01:00June 23rd, 2022|

šŸ“£Check out this study protocol just out from Dr Cathal O’Connor ICAT fellow at the INFANT Research Centre University College Cork

šŸ’”In this paper Cathal assesses #sleep in infants with early-onset #atopicdermatitis by longitudinal evaluation

Read publication here

Wellcome Trust #atopicdermatitis #paediatric #dermatology #sleep #UCCResearch

INFANT Spin-Out ‘CergenX’

By |2022-06-16T14:58:16+01:00June 16th, 2022|

INFANT Spin-Out CergenX is using recent advances in Artificial Intelligence (AI) for the early detection of abnormal brain activity in babies at birth.

Founded in 2021, Cergenx aims to improve brain health monitoring in newborns by developing algorithms for screening all babies at birth for abnormal brain activity.

The technology will enable early intervention by medical professionals to improve outcomes for newborn babies.

The start-up says at least five in every 1,000 newborn babies may have some degree of brain injury. Unfortunately, this is often undetected until the infant is much older when parents notice developmental problems, which can have lifelong consequences.

Currently, the most common method for assessing brain function in newborn babies involves the use of electroencephalography (EEG) which measures the tiny electrical impulses of the brain. However, EEGs are complex to read, time consuming and there is often a shortage of trained specialists available. It is therefore not possible to test all newborn babies.

According to Cergenx (CSO) Geraldine Boylan, early detection of abnormal brain activity is critical.

ā€œThe majority of brain development takes place within the first few years of life so early detection of any abnormal brain activity is critical. Early detection is essential for improving the outcome for the child and indeed their family. There are a growing range of treatments and interventions available for newborn brain injury, but we need to know which babies are at highest risk as soon as possibleā€

The company has a large brainwave databank for training brain screening AI algorithms which will be embedded in medical devices.

Jason Mowles, CEO commented, ā€œWe are in discussions with medical device manufacturers who are interested in incorporating our software solutions into their devices. This is the start of a revolution in the use of AI for newborn brain healthcare, and Cergenx intends to be at the forefront of this.ā€

He continued, ā€œThis is incredibly exciting and rewarding work and we have a real opportunity to make a major difference in a vital area of newborn healthcare.ā€

Donnchadh Cullinan, Head of ICT High Potential Start-Up, Enterprise Ireland, said, ā€œCergenx has the potential to transform infant healthcare, and to have a real impact on the lives of infants and families around the world. The leadership team at Cergenx are an excellent example of Ireland’s rich collaborative ecosystem at work, and Enterprise Ireland is proud to support and back the next generation of Irish businesses who are creating innovative solutions to complex and challenging issues every day.ā€

Cergenx is a spin out from the INFANT Research Centre at University College Cork (UCC). The INFANT Centre has been at the forefront of newborn brain research since it was founded by Professor Geraldine Boylan in 2013.

Professor Boylan co-founded Cergenx in conjunction with Jason Mowles (CEO) and Sean Griffin (CTO) to bring the benefits of this research to newborn babies worldwide.

The company has assembled a diverse team with expertise in the newborn brain, AI, commercialisation, software development, finance, funding and regulatory expertise to achieve this goal.

UCC’s Director of Innovation, Dr Sally Cudmore, congratulated the Cergenx team saying ā€œThis new UCC spin-out company is a strong example of the potential of clinical research to directly improve neonatal health care. Cergenx will convert many years of excellent UCC research into technologies for direct clinical use to improve patient outcomes for infants.ā€

 

About Cergenx:

Cergenx was founded in 2021 to develop algorithms and systems for monitoring and detection of brain abnormalities at scale. The company is focused on leveraging research in this area to develop and commercialize algorithms for detection of abnormal activity. Cergenx is an Enterprise Ireland High Potential Start Up (HPSU) company, www.globalambition.ie/HPSU

INFANT Seminar Series

By |2022-06-14T11:35:54+01:00June 14th, 2022|

šŸ“£INFANT Seminar Series continues this Friday!
Ā 
šŸ—£Clinical Research Fellow Dr. Jurate Panaviene will present
Ā 
šŸ’”Interim results of 50 infants enrolled in The NIOMI study: “Non-Invasive Lung Oxygen Monitoring in Term Infants’’. This clinical observational study is aiming to evaluate if a non-invasive GASMAS-based technology incorporated into Lung analyzer can detect oxygen and measure oxygen concentration in the lungs of healthy full-term infants.

INFANT Researchers presenting at the Irish Association for Allergy & Immunology Meeting

By |2022-06-07T10:41:19+01:00June 7th, 2022|

šŸ“£INFANT Research CentreĀ attended the Irish Association of Allergy and Immunology (IAAI) Annual Meeting in Mullingar

šŸ—£Dr Bailey Crowley gave the presentation:

šŸ’”’Observational Study: Sublingual Immunotherapy Compliance In The Paediatric Population’

šŸ—£Caoimhe CroninĀ gave the presentation:

šŸ’” ‘Education in AAI administration and anaphylaxis management in the paediatric allergy clinic: What we have learned so far’

šŸ“£Dr.Ā Juan Enrique Trujillo WurtteleĀ also took part in the meeting and is the Principal Investigator for the projects presented.

#ImmunotherapyĀ #UCCResearchĀ #AllergyResearch

Pregnancy Loss Research Group Win Research Group of the Year 2022

By |2022-06-07T10:01:21+01:00June 7th, 2022|

Last week the Pregnancy Loss Research Group at University College Cork and Cork University Maternity Hospital led by Prof Keelin O’Donoghue was awarded ā€˜Best Research Team of the year’ at the UCC Research awards.

This multidisciplinary teamĀ  is made up of doctors, midwvies, nurses, administrative staff, social workers, chaplains, health services/population health/ social science researchers, and parent advocates, and is funded by funders The Irish Research Council, The Health Research Board, Science Foundation Ireland, and the HSE.

What are the aims of the group?
  • Examine lifestyles and psycho-social demographic factors associated with all types of pregnancy loss
  • Calidate potential multiple risk factors and biomarkers that may be used to predict pregnancy loss.
  • Develop a research-based approach to the introduction of new materials to improve the process of consent for autopsy
  • Discover bereaved parents’ attitudes to autopsy and post-mortem investigations
  • Explore the psychological and spiritual needs of bereaved parents
  • Examine the lived experiences of men and women who have experienced early pregnancy loss, late miscarriage, stillbirth and neonatal death
  • Explore bereaved parents’ attitudes and experiences, and then to assess how this interacts with biological or socio-demographic causes of pregnancy loss.
  • Improve understanding and increase awareness of the consequences of pregnancy loss amongst healthcare professionals
  • Examine the impact and costs of pregnancy loss in the next pregnancy on parents and healthcare professionals

Learn more about the Pregnancy Loss Research Group Here

Go to Top